Search

Displaying results 1211 - 1220 of 4588 in total
  1. Drug

    Cefotaxime

    go.drugbank.com/drugs/DB00493
    ApprovedInvestigational

    Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to c...

  2. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    [A178945] Thus brimonidine is an effective and safe alternative to beta-blockers, in patients with, or at high risk for, cardiopulmonary disease. … [A178948,A178969] Ophthalmically, brimonidine is used to lower intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

  3. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...

  4. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.

  5. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and ...

  6. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]

  7. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

  8. Drug

    Sitimagene ceradenovec

    go.drugbank.com/drugs/DB04907
    Experimental

    It is being developed by Ark Therapeutics. … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy

  9. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    ORG-34517 is currently under investigation by Organon for the treatment of depression. … It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.

  10. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opa...